FILSPARI (Sparsentan) – IgAN | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Sparsentan / FILSPARI®
  • Indications: IgAN
  • Dosage Form: ​ Tablet
  • Specification: 400 mg × 30 tablets/bottle

Sparsentan Application Scope

FILSPARI is a first-in-class, dual endothelin angiotensin receptor antagonist (DEARA). It blocks endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, reducing proteinuria and slowing kidney function decline in IgA nephropathy.

Indication:

  • Primary IgA nephropathy (IgAN): In adults at risk of rapid disease progression.

filspari sparsentan
filspari sparsentan

Sparsentan Characteristics

  • Ingredients: Active ingredient: Sparsentan
    Excipients: microcrystalline cellulose, povidone, magnesium stearate, etc.

  • Properties:​ Film-coated oral tablets.

  • Packaging Specification:​ 200 mg tablets, 90 tablets/bottle.

  • Storage:​ Store at 20–25°C. Protect from moisture.

  • Expiry Date: As indicated on package.

  • Executive Standard: ​FDA approval standard.

  • Approval Number: Per local authority.

  • Date of Revision: As indicated in insert.

  • Manufacturer: Travere Therapeutics, Inc.

Guidelines for the Use of FILSPARI

  • Dosage and Administration:

    • Recommended Dose: 400 mg orally once daily.

    • Administration: Swallow whole, with or without food.

    • Missed Dose:​ If a dose is missed, take as soon as remembered unless close to next dose. Do not double dose.

  • Adverse Reactions:

    • Common Adverse Reactions:

      • Peripheral edema

      • Hypotension, dizziness

      • Hyperkalemia

      • Anemia, fatigue

    • Serious Adverse Reactions:

      • Hepatotoxicity (elevated liver enzymes)

      • Embryo-fetal toxicity (contraindicated in pregnancy)

  • Contraindications:

    • Pregnancy (high teratogenic risk)

    • Hypersensitivity to sparsentan or excipients

  • Precautions:

    • Monitor liver function and serum potassium regularly

    • Teratogenic risk → use only under REMS program in the U.S.

    • Use with caution in patients with hypotension or renal impairment

Sparsentan Interactions

  • Avoid use with strong CYP3A inhibitors/inducers

  • Risk of hyperkalemia when combined with potassium-sparing diuretics or RAAS inhibitors

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo